IP Library Granted Patent US 9,423,404
Granted Patent B1
US 9,423,404 · App. 14/205,170 · Granted Aug 23, 2016

Method of screening for an agent that enhances beige fat adipogenesis

Inventor: Brian Jay Feldman (Stanford, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior Unviversity
G01N33/82C12N15/1138G01N33/5023G01N33/5041G01N33/5044G01N33/5073C07K14/70567
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,423,404
App. No.
14/205,170
Granted
Aug 23, 2016
Kind
B1
Abstract

Methods and compositions are provided for enhancing beige fat adipogenesis, and screening for agents having this activity An adipocyte progenitor cell is contacted with an effective dose of an antagonist of unliganded vitamin D receptor (VDR) activity. The contacting may be performed under adipogenic conditions.

Claims (12)

1. A method of screening for an antagonist agent that enhances human brown or beige fat adipogenesis mediated by unliganded vitamin D receptor (VDR) activity, the method comprising:

combining a candidate agent with a vitamin D receptor present in an intact human cell capable of adipogenesis and selected from a pre-adipocyte, an adipocyte progenitor, an adipocyte stem cell and a fibroblast; and

determining inhibition of unliganded VDR activity by differentiation of cells under adipogenic conditions to brown, beige or white adipocyte phenotypes in the absence or presence of a candidate agent;

wherein brown or beige fat adipogenesis is enhanced by interfering with unliganded VDR repression of UCP1 expression.

2. The method of claim 1 wherein the activity is occupancy of a vitamin D response element (VDRE).

3. The method of claim 1 wherein the unliganded vitamin D receptor (VDR) activity includes inhibiting VDR occupancy of a vitamin D response element (VDRE) in the absence of vitamin D or an analog thereof.

4. The method of claim 2 , wherein the VDRE is VDRE4 of UCP1.

5. A method of screening for an antagonist agent that enhances human brown or beige fat adipogenesis mediated by unliganded vitamin D receptor (VDR) activity, the method comprising:

contacting a candidate agent with a DNA comprising vitamin D response element 4 (VDRE4) in the absence of vitamin D or an analog thereof and determining if the agent occupies VDRE4 or inhibits VDR occupancy of VDRE4, and further testing the agent by the method comprising:

combining the agent with a human adipocyte or pre-adipocyte cultured in the presence of an adipogenic cocktail; and

determining inhibition of unliganded VDR activity by differentiation of cells under adipogenic conditions to brown, beige or white adipocyte phenotypes in the absence or presence of the candidate agent;

wherein brown or beige fat adipogenesis or adipocyte activity is enhanced by interfering with unliganded VDR repression of UCP1 expression.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2015
From: FELDMAN, BRIAN JAY
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 035304/0109 →
CONFIRMATORY LICENSE Recorded Jun 18, 2014
From: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 033194/0029 →
Continuity (1)
Provisional Application 61782301 · Mar 14, 2013